ClinicalTrials.gg
RecruitingNCT07578376Updated Nov 6, 2026

Empowered Relief® for Cancer Survivors With Chronic Pain

An interventional study of Empowered Relief Course (Zoom) in Chronic Pain Due to Cancer and Pain Catastrophizing, sponsored by University of Oklahoma. Recruiting at 1 site in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by University of Oklahoma · Not applicable, Interventional, and Treatment

How we know

Updated Nov 6, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
215
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,283 studies in Chronic Pain with a site in United States — 257 open to participants now, 348 under way, 7 of them phase 3. Chronic Pain · United States.

Planned enrollment
189th of 1,092
215 · median 60
Started
2027
with 11 others
No phase
803 of 1,283
168 open now
Primary completion
2029-12
later than 325 of 347 live
Registered
1,240th of 1,283
by date

Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 189th largest by planned enrollment of the 1,092 interventional ones that give a count, is one of 12 that started in 2027, is one of 803 with no phase, reaches primary completion later than 325 of the 347 other live ones, and was the 1,240th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

257 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:

251 more — sign in →

All 257 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,283 studies in Chronic Pain with a site in United States, or all of them as a file.
02

Study summary

This randomized controlled study to examine the efficacy of ER class in cancer survivors with chronic pain. Eligible participants will be randomly assigned to a ER class or a waitlist control condition. We will recruit 250 participants with a goal of having 200 completers (20% attrition). Participants in the control condition will be invited to attend ER class after the 3-month observation period.

Read the detailed description

The Empowered Relief (ER) study is a Zoom-based, 1-session, 2-hour, skills-based pain management class delivered by certified instructors. Participants learn three core pain relief skills, develop a personalized plan, and receive access to a free binaural audio app for daily use and supportive daily text messages. Participants will fill out a series of follow-up surveys at the 1, 2, and 3-month post-class mark. These surveys will be directly compared to surveys given to participants that do not complete the course. Class admittance will be randomized, however, participants not in the treatment group will have the option to take the course after the 3-month observatory period. ER has demonstrated moderate efficacy in individuals with chronic non-cancer pain, reducing pain intensity, pain interference, pain-related distress (pain catastrophizing), sleep disturbance, and anxiety. Because of its brief, didactic nature and delivery via Zoom, ER can accommodate large class sizes and may address access disparities among underserved cancer survivors. ER is currently being studied across various non-cancer populations and has been adopted as standard of care in leading healthcare institutions in the U.S. and abroad. Yet, Empowered Relief has not been tested in cancer survivors.

03

Conditions studied

  • Chronic Pain Due to Cancer
  • Pain Catastrophizing

Browse trials for

Keywords

  • Empowered Relief
  • Chronic Pain
  • Cancer survivor
  • Survey Study
  • Monthly follow-ups
  • Zoom class
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

History of cancer diagnosis, completion of active cancer treatment, cancer free at the time of enrollment, experience of body pain most or every day, pain duration at least 3 months, and English fluency.

Exclusion criteria

Exclusion Criteria:

Significant psychological and cognitive impairment that limits one's ability to complete study tasks (completion of online survey, attending the zoom-based ER class). Life-threatening acute illness (e.g., infection, heart attack, injury), and no access to a computer, a smartphone or a tablet.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
215 participants (estimated)

Study arms

  • Experimental
    Empowered Relief

    Participants in this arm of the study will complete the one-time 2hr Empowered Relief zoom course. They will also complete a post-course survey as well as the standardized 1, 2, and 3-month follow-up surveys.

    Behavioral: Empowered Relief Course (Zoom)

  • No intervention
    Wait-List Control

    Participants in the Wait-List Control (WLC) arm will not have initial access to the empowered relief course. Additionally they will not have to complete a post-course survey. The WLC group will be asked to complete the 1, 2, and 3-month follow-up studies after no intervention. After this 3-month observatory period, WLC participants will have voluntary access to the Empowered Relief course.

Interventions

  • BehavioralEmpowered Relief Course (Zoom)

    This is a one-time 2 hour long skills-based pain management class delivered by certified instructors. Participants learn three core pain relief skills, develop a personalized plan, and receive access to a free binaural audio app for daily use and supportive daily text messages.

06

What researchers measure

Primary outcomes

  1. Overall treatment satisfaction

    0-10 scale, higher scores indicate greater satisfaction, mean should be 8 or higher

    Time frame: Immediately after intervention

Secondary outcomes

  1. Pain Intensity

    0-10 scale, higher scores indicate higher pain

    Time frame: 1 month after intervention

  2. Pain Interference

    T-scores, higher scores indicate higher pain interference

    Time frame: 1 month after intervention

  3. Pain Intensity

    0-10 Scale, higher scores indicate higher pain

    Time frame: 3 months after intervention

  4. Pain Interference

    T-scores, higher scores indicate higher pain interference

    Time frame: 3 months after intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2029, 35 months later.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 35 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jan 2027, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 11, 2026
StartEst.
Jan 2027was Jun 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Apr 30, 2030
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→Jan 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Start date Jun 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07578376
Responsible party
Sponsor
First posted
May 11, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Nov 6, 2026

Study contacts

Sophia You, PhD, ABPP
Contact
Dokyoung-You@ou.edu
918-660-3923
Jordan Keast, BS
Contact
jordan-keast@ou.edu
Sophia You, PhD, ABPP
principal investigator · University of Oklahoma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion